Research Foundation

AVS was applied to elementary students with ADHD and behavior disorders across two school settings. Participants showed measurable improvements in attention, impulsivity, and reading scores — supporting AVS as a practical, non-pharmacological tool for nervous system modulation in real-world environments.

Rhythmic audio-visual stimulation produced measurable electrocortical and autonomic responses — including heart rate and skin conductance changes — alongside subjective feelings of relaxation and altered arousal. The study confirms that synchronized AV input directly entrains both the brain and the autonomic nervous system.

QEEG analysis in patients with refractory depression showed significant decreases in depression scores after four weeks of AVS at 14 Hz (beta frequency), using a crossover design with 16 participants. The mechanism — brainwave normalization visible on EEG in cortical regions associated with mood regulation — points toward AVS as a measurable neurological intervention, not just a relaxation tool.

Rhythmic visual stimulation phase-locked alpha oscillations in the visual cortex, showing that the brain actively entrains to sensory input at the same frequency. This foundational neuroscience study validates the core mechanism behind AVS: the brain synchronizes with external rhythmic stimulation, altering perception and cognitive processing.

Rhythmic visual stimuli caused local entrainment of alpha oscillations in the visual cortex and produced cyclic modulation of perceptual processing. This study provides direct neuroimaging evidence that sensory entrainment is a real, measurable phenomenon with functional consequences for how the brain processes information.

Open-loop AVS induced delta-frequency EEG activity in older adults with chronic osteoarthritis pain and insomnia. Delta induction — the brainwave state associated with deep restoration — was achieved non-invasively through external stimulation, suggesting clinical utility for pain modulation and stress recovery.

A pilot self-care study of adults with chronic pain and insomnia found that audio-visual stimulation, used independently at home, reduced pain intensity and improved sleep. Participants reported high satisfaction and tolerability, positioning AVS as a scalable, patient-driven adjunct to clinical care.

Direct EEG measurement during AVS confirmed frequency-specific changes in brainwave activity corresponding to the stimulation frequency. The study establishes a reliable, replicable link between stimulus frequency and neural response, providing the mechanistic foundation for frequency-targeted therapeutic applications.

A synthesis of over 20 studies found AVE effective for improving cognition, reducing behavioral problems, and alleviating stress and pain. Clinical studies showed declines in depression, anxiety, and suicidal ideation; seasonal affective disorder patients reported reductions in depression and anxiety alongside improved mood, energy, and social functioning. Note: this is a secondary synthesis, not a peer-reviewed study.

Twenty individuals diagnosed with Major Depressive Disorder completed a 5-week intervention of music listening combined with low-frequency vibroacoustic stimulation, self-administered at home. Significant reductions in depression symptoms, anhedonia, and improvements in sleep quality and quality of life were observed, with 37% of participants meeting full clinical response criteria and approximately 62% average symptom reduction among responders. The improvements in anhedonia among responders point to vibrotactile stimulation as a potential modulator of reward-processing circuits.

Vibratory stimulation applied to the body produced significant pain alleviation — one of the earliest controlled demonstrations of what became known as vibratory analgesia. The mechanism operates at the spinal cord level, where vibration modulates nociceptive signal transmission, providing the physiological foundation for VAT's pain applications.

A mechanistic review and experimental study examining how vibration reduces pain. Findings confirmed that vibratory stimulation activates mechanoreceptors that gate pain transmission at the spinal level — supporting vibroacoustic therapy's analgesic effects through a well-established neurophysiological pathway distinct from pharmacological pain management.

In a pediatric population with juvenile arthritis, combined physical and vibroacoustic therapy produced meaningful reductions in chronic pain compared to physical therapy alone. The results establish VAT's additive benefit in inflammatory pain conditions, including in younger patient populations.

A clinical review of vibroacoustic sound therapy across patient populations found consistent improvements in pain management alongside secondary benefits including reduced anxiety, decreased muscle tension, and improved mood. The authors position VAT as a practical, low-risk complement to standard pain care.

Elderly nursing home residents with depression received vibroacoustic therapy and showed measurable reductions in depressive symptoms on standardized assessment. The study supports VAT as an accessible, low-burden intervention with mental health benefits in older adult populations.

Low-frequency sound wave therapy in frail older adults improved functional capacity and blood circulation over the course of the intervention. These systemic physiological improvements suggest that VAT produces whole-body regulatory effects extending beyond the localized nervous system response.

In individuals with Rett syndrome, combined music and vibroacoustic stimulation produced measurable neurophysiological responses including EEG changes and autonomic markers of engagement. The study demonstrates VAT's ability to elicit neurological responses even in populations with severely limited sensory-motor communication.

Low-frequency vibratory stimulation at 40 Hz induced neurite outgrowth in mutant nerve cells (PC12m3) at approximately three times the rate produced by nerve growth factor alone — via activation of the p38 MAPK signaling pathway. This cellular-level finding suggests that vibroacoustic stimulation may significantly enhance neuroplasticity pathways, with implications for neurological repair and cognitive health.

A comprehensive review of VAT across clinical and non-clinical populations documented consistent effects on muscle tone reduction, pain relief, anxiety reduction, and relaxation. Wigram's foundational work established VAT as a credible therapeutic modality with cross-population utility.

A pilot study in a health resort environment testing a newly developed VAT device found significant improvements in relaxation, stress, and general wellbeing across participants. The study supports VAT deployment in wellness and integrative care settings as a standalone or adjunct modality.

Sana Health is conducting one of the largest non-drug clinical trials for fibromyalgia using audio-visual stimulation. The ongoing investigation reflects growing institutional interest in AVS and VAT as clinically serious, evidence-worthy interventions for chronic pain and treatment-resistant conditions. Note: this is an industry-sponsored trial rather than independent academic research.